Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163526 · ClinicalTrials.gov registry record
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 13
- Enrollment target
NCT01163526: Clinical Trial study, sponsored by Stanford University.
NCT01163526 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01163526 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
A research study of liver perfusion (how blood flows to the liver over time). We hope to learn whether perfusion characteristics of liver masses may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment.
Interventions
- PROCEDURE CT perfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-09 |
| Est. Completion | 2016-07 |
Why NCT01163526 stopped before completion
NCT01163526 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CT perfusion is the first listed.
NCT01163526 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01163526 about?
NCT01163526 is a clinical study titled "Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies". A research study of liver perfusion (how blood flows to the liver over time). We hope to learn whether perfusion characteristics of liver masses may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment.
What is the current status of trial NCT01163526?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2010-09. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01163526?
The interventions under investigation include: CT perfusion (PROCEDURE).
Who is sponsoring clinical trial NCT01163526?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia